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INTRODUCTION
The number of people with diabetes mellitus (DM) worldwide is rapidly increasing. There are currently more than 170 million people with diagnosed DM, and that number has been predicted to rise to more than 360 million by 2030. 1 In Iran, 7.7% of adults aged 25 to 64 (approximately 2 million people) have been diagnosed with DM, and 16.8% of them (about 4.4 million) have impaired fasting glucose. 2 DM is an endocrine disorder, and its complications are a major cause of disability and hospitalization, posing a significant financial burden.
Dyslipidemia [elevated plasma levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C) and triglycerides (TG) and a low concentration of highdensity lipoprotein-cholesterol (HDL-C)] is one of the most common complications of DM. It plays a significant role in the development of premature atherosclerosis, coronary insufficiency and myocardial infarction. 3 Lipid profile abnormalities in diabetes are mediated through derangements in a variety of regulatory processes, especially insulin deficiency, thereby rendering diabetic patients more prone to hypercholesterolemia and hypertriglyceridemia. 4 Treatment of hyperlipidemia in diabetes involves improving glycemic control, getting exercise and using lipid-lowering diet and drugs. 5 At present, dyslipidemia is most commonly treated with lipid-lowering drugs, some of which are associated with serious adverse side effects. Thus, the effects of dietary components on plasma lipid metabolism have recently received considerable attention, highlighting the importance of natural products as lipid metabolism regulators. 6 Many medicinal plants have been found to be useful to successfully manage hyperlipidemia; these include Dracocephalum kotschyi, 7 Allium porrum, 8 purslane, 9 Eclipta prostrata, 10 Scoparia dulcis, 11 Trigonella foenum-graecum and red yeast rice. 12 However, only a limited amount of clinical research exists to support their efficacy.
Peucedanum pastinacifolium Boiss & Hausskn. is a plant belonging to the Apiaceae family, commonly known as "Alafe-Tofangchi". The plant is eaten by people in the center and western regions of Iran, and it is believed to be useful as an antihyperlipedimic plant. A survey of the literature revealed no pharmacological studies of this plant. Some species of Peucedanum have been used as anti-inflammatory, analgesic and diuretic compounds in Europe, 13 and some members of the family have antispasmodic, 14 antihypertension, 15 antihypeglycemic, 16 antitumor, antibacterial 17 and antiplatelet aggregation activities. 18 The most important chemical constituents of the genus Peucedanum are furanocoumarines, which have been isolated from several species. 14, [18] [19] [20] We previously demonstrated the hypolipidemic activity of the P. pastinacifolium plant in cholesterol-fed rats. 21 There are several reports that hyperglycemia is accompanied by increases in serum TC and TG levels in streptozotocin (STZ)-induced DM. 22, 23 In the present study, we investigated the hypolipidemic effect of a P. pastinacifolium extract in STZ-induced diabetic rats. Diabetes mellitus was artificially induced by a single intraperitoneal (i.p.) injection of a freshly prepared STZ solution (Sigma, St. Louis, MO, USA) dissolved in 0.1 M citrate buffer, pH 4.5, at a dose of 60 mg/kg Body Weight (BW) to overnight-fasted rats. 24 Control rats received an i.p. injection of citrate buffer alone. At three days postadministration, rats with stabilized diabetes, as indicated by a fasting blood glucose level of more than 250 mg/dl, were selected for the study. Treatment was started on the fourth day after STZ administration and continued for 30 days.
MATERIALS AND METHODS

Plant
Treatment protocol: The care and handling of rats were in accordance with the internationally accepted standard guidelines for use of animals, and the protocol was approved by our institutional committee on animal care. Normal and STZ-diabetic rats were randomly assigned to seven groups of six as follows:
Group I. Control rats receiving citrate buffer Group II. Diabetic control rats Groups III -V. Control rats orally treated with different doses of plant extract (125, 250, 500 mg/kg BW) in aqueous solution for 30 days.
Group VI. Diabetic rats fed with glibenclamide (5 mg/kg BW) in aqueous solution for 30 days.
Groups VII -IX. Diabetic rats orally treated with different doses of plant extract (125, 250, 500 mg/kg BW) in aqueous solution for 30 days.
At the end of the experimental period, the rats were anesthetized and killed by cervical dislocation. Blood samples were collected and the serum was separated by centrifugation (2000 g, 20 min, and 4°C) and submitted to biochemical analysis. The serum concentrations of glucose, TC, TG, LDL-C and HDL-C were determined with the use of commercially available enzyme kits (Pars Azmoon, Tehran, Iran). The atherogenic index [total cholesterol -HDL-C)/ HDL-C] was calculated.
Statistical analysis: The results are presented as mean ± SD. Statistical analysis of the data was performed using an unpaired t-test and analysis of variance (ANOVA) with SPSS/11.5 software. Significant differences are indicated by p-values of less than 0.05.
RESULTS
The serum lipid profiles of the control (group I) and STZ-induced diabetic rats (group II) are shown in Table 1 . A significant (P < 0.05) increase in the levels of serum total cholesterol, triglyceride and LDL-C were observed in the diabetic rats, whereas the HDL-C level was markedly (P < 0.05) decreased compared to normal control rats (Table 1) . Table 2 shows the serum lipid profiles of the untreated control group (group I) and control groups treated with different doses of PPE (groups III-V). The treatment of control rats with PPE did not significantly affect any of the evaluated parameters (Table 2) . Diabetic rats treated with PPE (group IX) or glibenclamide (group VI) for 30 days had significantly reduced serum total cholesterol, triglyceride and LDL-C levels, whereas the HDL-C level was significantly increased compared to control diabetic rats (group II). Drug treatment restored these values to near control group levels (Table 3) . Finally, the atherogenic index in groups treated with PPE (groups IX) or glibenclamide (group VI) were significantly decreased compared with the diabetic control group (group II). The treated animals had values similar to the normal levels seen in the control group (Table 4 ). The body weights and blood glucose levels at the initiation and end of the study period in normal and diabetic control groups are shown in Table 5 .
DISCUSSION
DM is associated with profound alterations in the serum lipid and lipoprotein profiles and with an increased risk of coronary heart disease. 5 Lowering serum lipid levels through dietary changes or drug therapy is associated with a decrease in the risk of vascular disease and related complications. Values are the mean ± SD (n=6). * Represents a significant difference from the normal control group at P<0.05. LDL-C: Low-Density Lipoprotein-Cholesterol, HDL-C: High-Density Lipoprotein-Cholesterol, STZ: Streptozotocin Values are the mean ± SD (n=6). * Represents significant difference from diabetic control group at P<0.05. LDL-C: Low-Density Lipoprotein-Cholesterol, HDL-C: High-Density Lipoprotein-Cholesterol, TC: Total Cholesterol, TG: Triglycerides, PPE: Peucedanum pastinacifolium hydroalcoholic Extract, STZ: Streptozotocin In the present study, the ability of PPE to partially reverse the hyperlipideimia of STZ-induced diabetic rats is confirmed. Induction of diabetes in rats by administration of STZ led to the development of dyslipidemia. In our study, a marked increase in the lipid content of serum was found in STZ-induced diabetic rats ( Table 1 ). The increase in the total serum cholesterol, triglyceride and LDL-C levels in the diabetic rats is mainly due to increased mobilization of free fatty acids from peripheral deposits, as insulin inhibits the hormone-sensitive lipase. The increase in the serum LDL-C level may also result from glycosylation of the lysyl residues of apoprotein B, which leads to a decrease in LDL metabolism due to a decrease in the affinity of LDL for its receptors. Our results show that the serum HDL-C level decreased in STZ-induced diabetic rats (Table 1) . A number of observations indicate that the plasma HDL-C level is low in untreated diabetics . 26 The hypolipidemic potency of PPE following daily administration indicated that it effectively reduces serum TC, TG and LDL-C levels and increases the serum HDL-C level in diabetic rats. Importantly, it had no effect on serum lipid profiles in normal rats (Tables 2 and 3 ).
The mechanism(s) of the hypolipidemic actions of PPE are not known; however, they could be mediated by control of tissue metabolism and improved insulin secretion and action because insulin lowers lipid levels and normalizes lipids in STZ-induced diabetic rats. 27 The increase in the HDL-C level achieved by PPE significantly decreased the treated rats' atherogenic index ( Table 4 ). The HDL level inversely correlates with the risk of atherosclerotic cardiovascular disease. HDLs protect against or reverse atherosclerosis by their ability to serve as acceptor particles for macrophage cholesterol efflux, prevention of endothelial dysfunction and maintenance of endothelial integrity. 28, 29 Thus, PPE has the potential to prevent the formation of atherosclerosis and coronary heart disease, which are secondary diabetic complications of severe DM.
In conclusion, alterations in lipid profiles were restored to near normal levels by PPE treatment of rats with experimentally induced diabetes. Several authors reported that secondary metabolites, such as furanocoumarines, saponins, flavonoids, phenolic compounds, and triterpenoids, have hypolipidemic activity. [30] [31] [32] Hence, the hypolipidemic and anti-atherogenic properties of PPE may be due to different types of active secondary metabolites, each with a single or diverse range of biological activities. Further biochemical and pharmacological investigations are in progress to isolate and identify the active compounds in P. pastinacifolium.
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